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Tyrosine kinase inhibitors (TKIs), such as Tarceva 
(erlotinib), Iressa (gefitinib), Tykerb (lapatinib), and 
Gleevec (imatinib), are among the most broadly applied 
cancer therapeutics. By blocking the tyrosine kinase 
activity of mutated or overexpressed oncogenes, such as 
Epidermal Growth Factor Receptor (EGFR) and human 
epidermal growth factor receptor 2 (HER2), they 
interfere with signaling cascades which cancer cells are 
frequently “addicted” to, inducing vigorous and 
prolonged clinical responses in responsive patients [1]. 
Nevertheless, particularly in solid cancers, patients will 
sooner or later face relapses due to the emergence of 
resistant cell clones. Thus, strategies to safely increase 
the effectiveness of TKIs, but also reduce their toxicity 
are critically needed.  
Studies show that cycles of prolonged fasting (PF, water 
only for more than two days) or of fasting-mimicking 
diets (FMDs) enhance the activity of chemo- and radio-
therapy in preclinical cancer models [2, 3]. In addition, 
another advantage of administering chemotherapy 
during PF is that its overall tolerability appears to be 
increased [4]. As a result, several clinical trials are 
currently exploring the effects of PF/FMDs in patients 
undergoing chemotherapy (NCT01304251, 
NCT01175837, NCT00936364, NCT01175837, 
NCT01802346, NCT02126449). 
Given this background, it is important to ask whether 
starvation would also be a useful approach to increase 
the efficacy of TKIs [5]. Results show that starvation 
strongly potentiates the antitumor activity of these 
agents both in vitro and in vivo in mice carrying human 
tumor xenografts. This goes along with a marked 
increase in the ability of TKIs to block signaling via the 
pro-tumorigenic mitogen-activated protein kinase 
(MAPK) cascade when they are administered under 
starvation conditions. Gene expression microarrays 
indicated that starvation and crizotinib (a TKI that is 
commonly used in advanced non-squamous non-small-
cell lung cancer with EML4-ALK translocation) lead to 
similar changes in gene expression (primarily affecting 
cell cycle and DNA repair genes), whereas combining 
the two treatments compounds such effects by 
activating E2F6 (a dominant negative inhibitor of other 











cell cycle-promoting transcription factors E2F1 and 
E2F4.  
Overall, this work indicated that PF and FMDs, recently 
shown to be effective in reducing IGF-1 levels in both 
mice and human subjects [6], may not only be effective 
when coupled to standard chemotherapy or to 
radiotherapy, but that they may also find applications in 
patients receiving more modern, molecularly-targeted 
agents, such as TKIs, making them more effective. That 
being said, this study also left several questions open 
and opportunities for investigations. Do PF/FMDs also 
reduce the likelihood of secondary resistance (or delay 
its occurrence), thereby extending progression-free 
survival and overall survival? Can PF/FMDs achieve 
cases of advanced solid cancers cured with TKIs? Do 
PF/FMDs also increase the activity of commonly used 
anti-EGFR and anti-HER2 monoclonal antibodies, such 
as cetuximab or trastuzumab? Last, but not least, can 
PF/FMDs also increase the tolerability of TKIs, as 
much as they do with chemotherapeutics? Indeed, 
although the toxicity of TKIs is typically less severe 
that of chemotherapy, it can still be invalidating and 
lead to dose reductions or treatment discontinuations 
[1]. Reduced toxicity is anticipated considering the 
already demonstrated differential regulation of the 
growth of normal vs. cancer cells by PF/FMDs, which 
would promote entry of many normal cell types into a 
non-dividing and protected mode and make them less 
dependent on tyrosine kinase activity. Thus, if 
PF/FMDs helped spare healthy tissues from the toxicity 
of TKIs, the overall effectiveness of these agents could 
be strongly improved [7]. Answering these questions 
through preclinical and clinical studies is going to be 
crucial to provide a clear frame of usefulness for 
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